FDA Approves HIV Drug for Full-Term Newborns
The regulatory body authorized the use of dolutegravir for infants born to mothers living with HIV-1 as of August 2026.
Updated on Oct. 22, 2026 in Babies
Live Poll
Do you believe medical research developments typically result in improved health outcomes for the general public?
In August 2026, the FDA approved the use of the antiretroviral medication dolutegravir to treat HIV-1 in full-term infants from birth to four weeks old. To qualify for the treatment, newborns must weigh at least two kilograms.
Why it matters
Newborns process medications differently than older children and adults, and they have historically faced a shortage of approved antiretroviral options. This approval provides a new pathway for managing HIV-1 exposure in the earliest stages of life.
The clinical trial enrolled 48 full-term newborns across three countries to assess safety over a 16-week period. Infants are required to meet a minimum weight of two kilograms to safely receive the medication.
The players
FDA
The Food and Drug Administration is the United States federal agency responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.
IMPAACT
The International Maternal Pediatric Adolescent AIDS Clinical Trials Network conducts global research to evaluate the safety and effectiveness of treatments for HIV and related infections.
The details
The treatment regimen was developed through the IMPAACT 2023 Phase 1 clinical trial, which confirmed that the dosing schedule achieves necessary drug levels in newborns. Study participants, born to mothers living with HIV-1, were monitored for safety throughout the 16-week investigation period.
Timeline
The FDA announced the expanded approval for the drug in August 2026.
Culture Shift
This development represents a milestone in pediatric pharmacology, moving away from a lack of neonatal-specific treatment options. It follows the findings of the IMPAACT 2023 clinical trial, which bridges the gap between adult HIV protocols and neonatal medical needs.
Parents and caregivers of infants born to mothers with HIV-1 should consult with healthcare providers regarding the eligibility criteria for this treatment. Ensuring an infant meets the two-kilogram minimum weight is a critical factor for safely initiating this therapy.
The takeaway
This approval marks a significant step forward in ensuring that newborns have access to effective antiretroviral therapy. Families should work closely with pediatric specialists to monitor health outcomes and maintain appropriate dosing schedules during the initial weeks of life.
Further reading
For more on pediatric health developments, visit the Babies section.
Live Poll
Do you believe medical research developments typically result in improved health outcomes for the general public?
